Department of Pharmacy Practice and Science, Division of Health Services Research, University of Iowa, Iowa City, IA, USA.
Steadman Hawkins Clinic of the Carolinas, Prisma Health - Upstate, Greenville, SC, USA.
J Shoulder Elbow Surg. 2020 Jul;29(7S):S115-S125. doi: 10.1016/j.jse.2020.04.037. Epub 2020 Jun 9.
Prescription opioids are standard of care for postoperative pain management after musculoskeletal surgery, but there is no guideline or consensus on best practices. Variability in the intensity of opioids prescribed for postoperative recovery has been documented, but it is unclear whether this variability is clinically motivated or associated with provider practice patterns, or how this variation is associated with patient outcomes. This study described variation in the intensity of opioids prescribed for patients undergoing rotator cuff repair (RCR) and examined associations with provider prescribing patterns and patients' long-term opioid use outcomes.
Medicare data from 2010 to 2012 were used to identify 16,043 RCRs for patients with new shoulder complaints in 2011. Two measures of perioperative opioid use were created: (1) any opioid fill occurring 3 days before to 7 days after RCR and (2) total morphine milligram equivalents (MMEs) of all opioid fills during that period. Patient outcomes for persistent opioid use after RCR included (1) any opioid fill from 90 to 180 days after RCR and (2) the lack of any 30-day gap in opioid availability during that period. Generalized linear regression models were used to estimate associations between provider characteristics and opioid use for RCR, and between opioid use and outcomes. All models adjusted for patient clinical and demographic characteristics. Separate analyses were done for patients with and without opioid use in the 180 days before RCR.
In this sample, 54% of patients undergoing RCR were opioid naive at the time of RCR. Relative to prior users, a greater proportion of opioid naive users had any opioid fill (85.7% vs. 75.4%), but prior users received more MMEs than naive users (565 vs. 451 MMEs). Providers' opioid prescribing for other patients was associated with the intensity of perioperative opioids received for RCR. Total MMEs received for RCR were associated with higher odds of persistent opioid use 90-180 days after RCR.
The intensity of opioids received by patients for postoperative pain appears to be partially determined by the prescribing habits of their providers. Greater intensity of opioids received is, in turn, associated with greater odds of patterns of chronic opioid use after surgery. More comprehensive, patient-centered guidance on opioid prescribing is needed to help surgeons provide optimal postoperative pain management plans, balancing needs for short-term symptom relief and risks for long-term outcomes.
在肌肉骨骼手术后,处方类阿片是术后疼痛管理的标准治疗方法,但目前尚无最佳实践的指南或共识。有记录表明,术后恢复期间开具的阿片类药物的强度存在差异,但尚不清楚这种差异是出于临床需要还是与提供者的实践模式有关,或者这种变化与患者的结果有何关联。本研究描述了接受肩袖修复术(RCR)的患者开具的阿片类药物的强度差异,并探讨了与提供者处方模式和患者长期阿片类药物使用结果的关联。
利用 2010 年至 2012 年的医疗保险数据,确定了 2011 年新出现肩部抱怨的 16043 例 RCR 患者。创建了两种围手术期阿片类药物使用的测量方法:(1)RCR 前 3 天至后 7 天期间任何阿片类药物的使用情况;(2)在此期间所有阿片类药物使用的总吗啡毫克当量(MME)。RCR 后持续性阿片类药物使用的患者结局包括:(1)RCR 后 90 至 180 天期间任何阿片类药物的使用情况;(2)在此期间没有任何 30 天的阿片类药物供应空白期。使用广义线性回归模型来估计提供者特征与 RCR 阿片类药物使用之间以及阿片类药物使用与结局之间的关联。所有模型均调整了患者的临床和人口统计学特征。对 RCR 前 180 天有或没有阿片类药物使用的患者分别进行了分析。
在该样本中,54%的 RCR 患者在 RCR 时为阿片类药物初治者。与之前的使用者相比,更大比例的阿片类药物初治者使用了任何阿片类药物(85.7% vs. 75.4%),但之前的使用者接受的 MME 比初治者多(565 比 451 MME)。其他患者的阿片类药物处方与 RCR 期间接受的围手术期阿片类药物强度有关。RCR 期间接受的总 MME 与 RCR 后 90-180 天持续使用阿片类药物的几率较高有关。
患者接受的术后疼痛阿片类药物的强度似乎部分取决于提供者的处方习惯。接受的阿片类药物强度增加与手术后慢性阿片类药物使用模式的几率增加有关。需要更全面、以患者为中心的阿片类药物处方指导,以帮助外科医生提供最佳的术后疼痛管理计划,在满足短期症状缓解需求和长期结果风险之间取得平衡。